Browse drugs

…Background The use of immunotherapy (IO) has dramatically changed the treatment landscape for non-melan…

…838159References Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung canc…

…ein acetylation in exhausted T cells. Additionally, deletion of Slc25a1 reduces exhaustion and improves tumor control in adoptively tra…

…Background Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy remains the cornerstone for managing high-r…

… dyes, and added to low-adhesion well-plates with interferon-γ (IFNγ). Clustering was monitored by fluorescence microscopy for hours…

…d FDA approval for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic NSCLC progressing after platinum therapy. The cur…

… be more prominent in patients receiving FOLFIRINOX rather than gemcitabine/nab-paclitaxel treatment. Further, preliminary analysis suggest…

…olic enzymes. Functional studies used pharmacologic inhibition (GW6471 for PPARα, etomoxir for fatty acid oxidation) and genetic knock…

…mmune suppression in GBM.Methods Nociceptors were ablated using resiniferatoxin. The myeloid-intrinsic role of the neuropeptide, calcitonin gen…

…control and extended survival.Conclusions In summary, targeting Fli-1 enhances CD8 + T cell antitumor activity and may represent a pr…

…tes such as the liver, which is significantly more resistant to checkpoint inhibitors (ICIs).Methods Using syngeneic melanoma cells, we optimized int…

…40425-018-0382-2Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl …